

IN THE CLAIMS:

Amend the claims as follows.

Claims 1-16. (Canceled)

17. (New) A method for treating preventatively or curatively a kidney cancer comprising the administration to a subject of an effective dose of a PTHrP antagonist or a pharmaceutical composition containing it.

18. (New) Method according to claim 17, wherein said subject is a human subject.

19. (New) Method according to claim 17, wherein said kidney cancer is selected from the group consisting of papillary carcinoma (chromophiles), chromophobe cell carcinoma, Bellini carcinoma and unclassified renal cell carcinomas.

20. (New) Method according to claim 19, wherein said kidney cancer is clear cell carcinoma (CCC).

21. (New) Method according to claim 17, wherein the PTHrP antagonist or the pharmaceutical composition containing it inhibits or decreases the tumour growth and/or metastasis formation in kidney cancer and / or its metastatic developments.

22. (New) Method according to claim 21, wherein the metastatic developments are in the lung and in the liver.

23. (New) Method according to claim 17, wherein the kidney cancer is a solid malignant tumour.

24. (New) Method according to claim 17, wherein the PTHrP antagonist is a compound binding the PTHrP receptor and inhibiting partially or totally a binding of PTHrP to its receptor.

25. (New) Method according to claim 24, wherein the PTHrP antagonist is a PTHrP receptor antagonist.

26. (New) Method according to claim 25, wherein the PTHrP antagonist is a PTHrP competitive antagonist.

27. (New) Method according to claim 25, wherein the PTHrP antagonist is selected from PTH or PTHrP peptides comprising a substitution or a deletion of at least one amino acid of the sequence of PTH or PTHrP and a fragment of the peptide

PTH or PTHrP, optionally comprising a substitution or a deletion of at least one amino acid of their sequence.

28. (New) Method according to claim 25, wherein the PTHrP antagonist is selected from PTHrP (3-34), PTHrP (7-34), PTHrP (8-34), PTHrP (9-34), PTHrP (10-34), their amides and their variants.

29. (New) Method according to claim 25, wherein the PTHrP antagonist is a non-peptidic antagonist.

30. (New) Method according to claim 25, wherein the PTHrP antagonist is a TIP derivative.

31. (New) Method according to claim 17, wherein the PTHrP antagonist is a compound binding a ligand of the PTHrP receptor, and inhibiting partially or totally a binding of PTHrP to its receptor.

32. (New) Method according to claim 31, wherein the PTHrP antagonist is an anti-PTHrP antibody.

33. (New) Method according to claim 32, wherein the PTHrP antagonist is a humanised anti-PTHrP antibody.

34. (New) Method according to claim 32, wherein the anti-PThrP antibody is selected from a humanised antibody, a human antibody, a chimeric antibody, an antibody obtained from a hybridoma and a fragment thereof and a modified form of said fragment.

35. (New) Method according to claim 32, wherein the anti-PThrP antibody is a polyclonal or monoclonal antibody.

36. (New) Method according to claim 17, wherein the PThrp antagonist is a compound binding to the mRNA or gene of PThrp, and inhibiting partially or totally an expression of PThrp.

37. (New) Method according to claim 36, wherein the PThrp antagonist is selected from an antisense oligonucleotide of PThrp, a RNAi, a transcription factor repressing the expression of the PThrp gene and a compound reducing the stability of the PThrp mRNA.